Welcome to Fennec HEARS™

Home Page > Fennec HEARS™

The source for access support

At Fennec HEARS™, our priority is making sure patients and their support systems have the support they need now. Fennec HEARS™ is a single source program for both patient financial and product access support.

Affording PEDMARK

At Fennec, we don’t want cost to stand in the way of you getting PEDMARK.

If someone has commercial or private health insurance: Fennec HEARS™ may be able to offer copay assistance in the form of a $0 copay card

How to enroll:

Fennec HEARS™ Enrollment Form

If someone has Medicaid (government insurance): Copay assistance may be available through independent charities. Contact a Fennec HEARS™ Care Coordinator for a list of potential resources

NOTE: Independent copay assistance foundations have their own rules for eligibility. We can only refer someone to a foundation that supports their disease state. We cannot guarantee a foundation will help.

If someone is uninsured: The Fennec Patient Assistance Program is committed to providing access to PEDMARK for eligible patients without insurance coverage. To see if you qualify for assistance, call a Fennec HEARS™ Care Coordinator

Get started with our Care Coordinators

Fennec HEARS™ offers education, access, and reimbursement support, including:

In-home nursing support: PEDMARK administration by licensed nurses nationwide
Insurance-related support: Benefits investigation, prior authorization, and/or appeal process
Patient Assistance Program: Provides eligible patients with access to free product in accordance with the physician’s on-label prescribing decision
Quick Start Program: New patients experiencing delays in determining coverage approval may receive a free, limited supply of PEDMARK
Bridge Program: Existing patients experiencing insurance coverage interruptions may receive a free, limited supply of PEDMARK

A Fennec HEARS™ professional does not offer medical advice or replace discussions with a healthcare provider.

Contact a Fennec HEARS™ Care Coordinator at 1-833-7PEDMARK (1-833-773-3627)

from 9 am to 6 pm ET, Monday through Friday.

IMPORTANT SAFETY INFORMATION

Do not allow your child to receive PEDMARK if they have had a severe allergic reaction to sodium thiosulfate or any of the other ingredients in PEDMARK.

Allergic reactions can happen with PEDMARK and can be serious and life-threatening. Your healthcare provider will monitor your child for allergic reactions during the PEDMARK infusion. Your healthcare provider will stop the infusion and provide treatment if your child has an allergic reaction. If your child has an allergic reaction, your healthcare provider will give your child certain medicines before each PEDMARK infusion. Tell your healthcare provider right away if your child has any of these signs of an allergic reaction: rash, hives (raised bumps), chest tightness, wheezing, trouble breathing, swelling of the face, lips, tongue, or throat.

Changes in salt and potassium levels in the blood are common with PEDMARK but can also be serious. Your healthcare provider will do blood tests to check your child’s sodium and potassium levels before starting and as needed during treatment with PEDMARK. Tell your healthcare provider right away if your child develops any of the following signs or symptoms: feeling tired or weak, feeling restless, muscle weakness, seizures.

Nausea and vomiting are common with PEDMARK but can also be serious. Your healthcare provider will give your child medicines before each PEDMARK infusion to help prevent nausea and vomiting.

The most common side effects of PEDMARK include decreased red blood cells (anemia).

These are not all the possible side effects of PEDMARK. Call your child’s doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Fennec Pharmaceuticals, Inc. at 1-833-336-6321.

Please see full Prescribing Information, including Patient Information, for PEDMARK.

WHAT IS PEDMARK?

PEDMARK is a prescription medicine used to decrease the risk of hearing loss in children 1 month of age and older who are receiving cisplatin for solid tumors (cancer) that have not spread to other parts of the body.

It is not known if PEDMARK is safe and effective when given after cisplatin infusions longer than 6 hours.

It is not known if PEDMARK is safe and effective in children less than 1 month of age. PEDMARK is not recommended in children younger than 1 month of age.